Foamix Reports First Quarter 2017 Financial Results and Provides Business Update

REHOVOT, Israel, May 9, 2017 /PRNewswire/ — Foamix Pharmaceuticals Ltd.(FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today financial results for the three months ended March 31, 2017.